Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

14.98 +0.25 (+1.70%)
Streaming Delayed Price Updated: 11:20 AM EDT, Mar 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Where uniQure Stands With Analysts ↗
 
Via Benzinga
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Why ToughBuilt Industries Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 209.5% to $2.29 after the company signed a Letter of Intention with UAE-Based e-script medicine management company Pharmak... 
Via Benzinga
News headline image
Why uniQure Stock Is Crashing Today ↗
Investors are focusing on the negative parts of the biotech company's interim results. 
Via The Motley Fool
News headline image
6 Analysts Have This to Say About uniQure ↗
 
Via Benzinga
News headline image
Analyst Ratings for uniQure ↗
 
Via Benzinga
Nasdaq Tumbles 1%; Patterson Companies Earnings Beat Views ↗
U.S. stocks traded mostly lower midway through trading, with Nasdaq Composite dropping over 100 points on Wednesday. 
Via Benzinga
News headline image
Uniqure Crashes To Six-Year Low On Muddy Results For Huntington's Gene Therapy ↗
The company is working on a one-time treatment for Huntington's disease. 
Via Investor's Business Daily
News headline image
Dow Drops Over 100 Points; Winnebago Industries Posts Downbeat Sales ↗
U.S. stocks traded lower this morning, with Dow Jones dropping over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.41% to 33,914.60 while the NASDAQ fell 0.31%... 
Via Benzinga
News headline image
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL Behring 
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure's Hemgenix Royalty Sales Agreement Extends Cash Runway, Relieves Near-Term Commercial Risk, Says Analyst ↗
uniQure N.V. (NASDAQ: QURE) agreed to sell a portion of the royalty rights due from CSL Behring from Hemgenix (etranacogene dezaparvovec-drbl) net sales to HealthCare Royalty and Sagard Healthcare  
Via Benzinga
News headline image
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
From uniQure Inc.
Via GlobeNewswire
News headline image
Recap: uniQure Q1 Earnings ↗
uniQure (NASDAQ:QURE) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:05 AM. Here's what investors need to know about the announcement. Earnings uniQure missed estimated earnings by... 
Via Benzinga
News headline image
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
News headline image
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs ↗
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per... 
Via Benzinga
News headline image
uniQure to Participate in Multiple Upcoming Industry Conferences in March
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Stock Trying To Close In On Key Technical Measure ↗
uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score. 
Via Investor's Business Daily
News headline image
uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market... 
Via Benzinga
News headline image
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
From uniQure Inc.
Via GlobeNewswire
News headline image
UniQure In-Licenses Early-Stage Amyotrophic Lateral Sclerosis Candidate, Analyst Says Deal Compliments Its Pipeline ↗
UniQure N.V. (NASDAQ: QURE) and Apic Bio entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). 
Via Benzinga
News headline image
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
From uniQure Inc.
Via GlobeNewswire
News headline image
3 Growth Stocks That Could Rocket Higher in 2023 ↗
Upcoming binary events could push these stocks to new all-time highs. 
Via The Motley Fool
News headline image
Newly Approved Drugs In US Command Over $200,000 On An Average ↗
The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.